Clinical Trial Update: IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (MATISSE) is evaluating IPH5201 in combination with durvalumab in patients with resectable non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• IPH5201

Snippet

Sponsor: Innate Pharma | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: RECRUITING